COR2ED

📣 Immunotherapy for HCC: Video update from #ESMO24 📣 How will new data on immunotherapy (IO) and IO-based treatments for HCC impact clinical practice? Dr Richard Finn joined us at ESMO to share his thoughts on new data presented at the congress and reveal his key clinical takeaways that HCPs need to know. Watch his video update and download the slides 👇📺 https://lnkd.in/etX55wFr Dr Finn reviews data from the following studies: ➡️ Five-year overall survival (OS) and OS by tumour response measures from the phase III HIMALAYA study of tremelimumab plus durvalumab in unresectable hepatocellular carcinoma (uHCC) Rimassa L, et al. (Abstract 947MO, ESMO2024) ➡️ Nivolumab (NIVO) plus ipilimumab (IPI) vs lenvatinib (LEN) or sorafenib (SOR) as first-line (1L) treatment for unresectable hepatocellular carcinoma (uHCC): Expanded analyses from CheckMate 9DW Decaens T, et al. (Abstract 965MO, ESMO 2024) ➡️ Transarterial Chemoembolization (TACE) With or Without Lenvatinib (len) + Pembrolizumab (pembro) for Intermediate-Stage Hepatocellular Carcinoma (HCC): Phase 3 LEAP-012 Study. Llovet J, et al. (Abstract LBA3, ESMO 2024) ➡️ Updated efficacy and safety data from IMbrave050: Phase 3 study of adjuvant atezolizumab (atezo) + bevacizumab (bev) vs active surveillance in patients (pts) with resected or ablated high-risk hepatocellular carcinoma (HCC) (Abstract LBA39, ESMO 2024) Yopp A, et al. AstraZeneca has provided a sponsorship grant towards this Independent Programme #MedicalEducation #Oncology

📣 Oncogene-addicted NSCLC highlights from #WCLC24 and #ESMO24📣 Dr Herbert Loong, MBBS FRCP FASCO (Hong Kong) shares his views on new oncogene-addicted non-small cell lung cancer (NSCLC) data from two major conferences: the World Conference on Lung Cancer (WCLC) and the European Society for Medical Oncology Congress, ESMO 2024. Watch his update below and download the slides 📺 👇 https://lnkd.in/eAsGq962 Dr Herbert Loong, MBBS FRCP FASCO reviews the data and shares his key clinical takeaways from the following studies: ➡️ TRUST-II: (Liu G, et al. Abstract MA06.03, WCLC 2024.) ➡️ LOXO-RAS-20001: (Fujiwara Y, et al. Abstract OA14.04, WCLC 2024.) ➡️ DESTINY-Lung03: (Planchard D, et al. Abstract OA16.05, WCLC 2024.) ➡️ SOHO-01: (Le X, et al. Abstract PL04.03, WCLC 2024.) ➡️ Beamion LUNG-1: (Ruiter G, et al. Abstract PL04.04, WCLC 2024.) ➡️ ALKOVE-1: (Drilon A, et al. Abstract 1253O, ESMO 2024.) ➡️ MARIPOSA: (Besse B, et al. Abstract LBA55, ESMO 2024.) #MedicalEducation #Oncology #LungCancer This programme is supported by an Independent Education grant from Bayer

📣 Immunotherapy for HCC: Video update from #ESMO24 📣 How will new data on immunotherapy (IO) and IO-based treatments for HCC impact clinical practice? Dr. Richard Finn joined us at ESMO to share his thoughts on new data presented at the congress and reveal his key clinical takeaways that HCPs need to know. Watch his video update 👇📺 Dr. Finn reviews data from the following studies: ➡️ Five-year overall survival (OS) and OS by tumour response measures from the phase III HIMALAYA study of tremelimumab plus durvalumab in unresectable hepatocellular carcinoma (uHCC) Rimassa L, et al. (Abstract 947MO, ESMO2024) ➡️ Nivolumab (NIVO) plus ipilimumab (IPI) vs lenvatinib (LEN) or sorafenib (SOR) as first-line (1L) treatment for unresectable hepatocellular carcinoma (uHCC): Expanded analyses from CheckMate 9DW Decaens T, et al. (Abstract 965MO, ESMO 2024) ➡️ Transarterial Chemoembolization (TACE) With or Without Lenvatinib (len) + Pembrolizumab (pembro) for Intermediate-Stage Hepatocellular Carcinoma (HCC): Phase 3 LEAP-012 Study. Llovet J, et al. (Abstract LBA3, ESMO 2024) ➡️ Updated efficacy and safety data from IMbrave050: Phase 3 study of adjuvant atezolizumab (atezo) + bevacizumab (bev) vs active surveillance in patients (pts) with resected or ablated high-risk hepatocellular carcinoma (HCC) (Abstract LBA39, ESMO 2024) Yopp A, et al. Watch this space for the summary slide set coming soon! AstraZeneca has provided a sponsorship grant towards this Independent Programme #MedicalEducation #Oncology

❗Update from #ESMO24 - Upper GI cancer data ❗ In this video, one of two filmed on-site at ESMO, Dr Elizabeth Smyth and Dr Samuel Klempner share their insights into upper GI cancer trial data emerging from the congress and the potential impact on clinical practice. In this video, the experts review data from the following studies: ➡️ Final overall survival for the phase 3, KEYNOTE-811 study of pembrolizumab plus trastuzumab and chemotherapy for HER2+ advanced, unresectable or metastatic gastric or gastroesophageal junction adenocarcinoma (Janjigian Y, et al. Abstract 1400O, ESMO 2024) ➡️ Trastuzumab deruxtecan monotherapy and combinations in patients with advanced/metastatic HER2-positive oesophageal, gastric or gastroesophageal junction adenocarcinoma: DESTINY-Gastric03 (DG-03) (Janjigian Y, et al. Abstract 1401O, ESMO 2024 ➡️Phase 3 study of SHR-1701 versus placebo in combination with chemo as first-line therapy for HER2-negative gastric/gastroesophageal junction adenocarcinoma (Peng Z, et al. Abstract LBA60, ESMO 2024) Watch the video update below 👇 This educational programme is supported by an Independent Educational Grant from Bayer #MedicalEducation #Oncology 📺

Update from #ESMO24 🧬 BRAF-altered colorectal and other cancers 🧬 Prof. Sebastian Stintzing and Prof. Reinhard Dummer discuss new data on BRAF-altered colorectal cancer, as well as BRAF-altered brain cancer, melanoma and solid tumours. 📺 Watch the video for their insights into the potential impact on clinical practice. 👇 The experts reviewed data from the following: ➡️ Abstract 515MO: Encorafenib + cetuximab + FOLFIRI for BRAF V600E-mutant mCRC: Updated results from the BREAKWATER safety lead-in. Tabernero J, et al. ➡️ Abstract 612O: Preliminary results from a phase 1 study of CFT1946, a novel BIDAC degrader in mutant BRAF V600 solid tumours. Vieito M, et al. ➡️ Abstract 613MO: A phase 1 clinical trial evaluating exarafenib, a selective pan-RAF inhibitor in combination with binimetinib in NRAS-mutant melanoma & BRAF-altered solid tumours. Cassier P, et al. ➡️ Abstract 453MO: A phase 1 study for safety, tolerability, pharmacokinetics, and anti-tumour activity of ABM-1310 in patients with BRAF V600 mutated recurrent primary brain tumours: interim result. Li W, et al. ➡️ Abstract LBA45: Early switch from targeted to immunotherapy in advanced BRAF V600-positive melanoma: Long-term OS and final PFS results of the randomised phase 2 ImmunoCobiVem trial. Schadendorf D, et al. This programme is supported by an Independent Medical Education Grant from Pierre Fabre. This content is not intended for HCPs within the UK. #MedicalEducation #Oncology

📣 Breast cancer data update from #ESMO24 📣 Prof. François-Clément Bidard joined us in Barcelona at the ESMO 2024 congress to share his perspective on the latest breast cancer data. How does he think these data will impact clinical practice? Watch his video update to find out 📺👇 Prof. François-Clément Bidard refers to the following trials: ➡️ Neoadjuvant pembrolizumab or placebo plus chemotherapy followed by adjuvant pembrolizumab or placebo for high-risk early-stage TNBC: Overall survival results from the phase 3 KEYNOTE-522 study. Schmid P, et al. (Abstract LBA4) ➡️ Trastuzumab deruxtecan in patients with HER2+ advanced/metastatic breast cancer with or without brain metastases: DESTINYBreast-12 primary results. Lin N, et al. (Abstract LBA18) ➡️ Adjuvant ribociclib plus nonsteroidal aromatase inhibitor in patients with HR+/HER2− early breast cancer: 4-year outcomes from the NATALEE trial. Fasching P, et al. (Abstract LBA13) #MedicalEducation #oncology

🚨 The latest GU oncology data from #ESMO24 🚨 Dr Ray Manneh Kopp shares his insights into new renal, bladder, and prostate cancer data presented at ESMO 2024. Watch his video update 📺👇 Dr Ray Manneh Kopp reviews data from the following trials: ➡️ A randomised multicenter open label phase 3 trial comparing enzalutamide vs a combination of Radium-223 and enzalutamide in asymptomatic or mildly symptomatic patients with bone mCRPC: First results of EORTC-GUCG 1333/PEACE-3 Gillessen S, et al. (Abstract LBA1) ➡️ A randomised phase 3 trial of neoadjuvant durvalumab plus chemotherapy followed by radical cystectomy and adjuvant durvalumab in muscle-invasive bladder cancer (NIAGARA) Powles T, et al. (Abstract LBA5) ➡️ Tivozanib–nivolumab vs tivozanib monotherapy in patients with RCC following 1 or 2 prior therapies including an immune checkpoint inhibitor – Results of the phase 3 TiNivo-2 Study Choueiri T, et al. (Abstract LBA73) #MedicalEducation #oncology

🚨Update from #ESMO24 - Upper GI cancer data 🚨 In this video, one of two filmed direct from ESMO, Dr Elizabeth Smyth and Dr Samuel Klempner share their insights into new upper GI cancer trial data and the potential impact on clinical practice. The experts review data from the following: ➡️ An international study evaluating pathological response to guide adjuvant FLOT chemotherapy in gastroesophageal cancer (SPACE-FLOT) (Lee M, et al. Abstract 1402MO, ESMO 2024) ➡️ A randomised phase 3 trial of perioperative chemotherapy with or without preoperative chemoradiotherapy for resectable gastric cancer (AGITG TOPGEAR): final results from an intergroup trial of AGITG, TROG, EORTC and CCTG (Leong T, et al. Abstract LBA58, ESMO 2024) Watch the video update below 👇 This educational programme is supported by an Independent Educational Grant from Bayer #MedicalEducation #Oncology 📺

🧬Update from #ESMO24 - BRAF-altered NSCLC 🧬 Dr Federico Cappuzzo & Prof. David Planchard joined us at ESMO 2024 to share their insights into new non-small cell lung cancer data presented at the congress. 📺 Watch the video to get their key takeaways and hear how they think these developments could impact clinical practice 👇 The experts review data from several key trials: ➡️ Updated efficacy and safety from the phase 2 PHAROS study of encorafenib plus binimetinib in patients with BRAF V600E-mutant mNSCLC. Riely G, et al. (Abstract LBA56) ➡️ Encorafenib plus binimetinib in patients with previously untreated BRAF V600E-mutant advanced NSCLC: an open-label, multicenter phase 2 trial (IFCT-1904 ENCO-BRAF). Planchard D, et al. (Abstract 1259MO) ➡️ First-line immunotherapy versus BRAF and MEK inhibitors for patients with BRAF V600E-mutant metastatic NSCLC. Di Federico A, et al. (Abstract 1299P) ➡️ Phase 2 trial of vemurafenib and cobimetinib in BRAF V600-mutated solid tumours and first-Line NSCLC: Australian Molecular Screening and Therapeutics (MoST) Substudy 12 Lin F, et al. (Abstract 623P) Supported by an Independent Education Grant from Pierre Fabre. This content is not intended for HCPs within the UK. #MedicalEducation #Oncology

❗ Update from #ESMO24: New lower GI cancer data ❗ In this video, one of two lower GI cancer updates from ESMO, Profs. Chiara Cremolini and Hans Prenen share their insights into new rectal and colorectal cancer data from the following trials: ➡️ NICHE-2 (Chalabi M, et al. Abstract LBA24, ESMO 2024) ➡️ NICHE-3 (De Gooyer P, et al. Abstract 503O, ESMO 2024) ➡️ IMHOTEP (De la Fouchardiere C, et al. Abstract 504O, ESMO 2024) Watch the video update to hear their views on how these data could impact clinical practice 👇 Check out our other posts for more expert insights on lower and upper GI cancer data presented at the congress 👀 Supported by an Independent Educational Grant from Bayer #Oncology #MedicalEducation 📺